Quarterly report · Q2
4543.TEDINET S100PLTQ
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥403.3bn | 2022-04-01 → 2022-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥206.0bn | 2022-07-01 → 2022-09-30d | Cons. | Revenue IFRS |
| Revenue | ¥703.3bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥344.6bn | 2021-04-01 → 2021-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥172.9bn | 2021-07-01 → 2021-09-30d | Cons. | Revenue IFRS |
| Operating income | ¥56.0bn | 2022-04-01 → 2022-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥25.5bn | 2022-07-01 → 2022-09-30d | Cons. | Operating profit loss IFRS |
| Operating income | ¥65.9bn | 2021-04-01 → 2021-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥29.6bn | 2021-07-01 → 2021-09-30d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥54.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥25.0bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥114.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥65.3bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥29.3bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥40.3bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥17.9bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥88.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥50.0bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥22.1bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥40.3bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥17.9bn | 2022-07-01 → 2022-09-30d | Cons. | Profit loss IFRS |
| Net income | ¥50.0bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥22.1bn | 2021-07-01 → 2021-09-30d | Cons. | Profit loss IFRS |
| Total assets | ¥1.66T | at 2022-09-30 | Cons. | Assets IFRS |
| Total assets | ¥1.47T | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.37T | at 2021-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥487.8bn | at 2022-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥461.4bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.17T | at 2022-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.01T | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥904.0bn | at 2021-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥856.7bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.17T | at 2022-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.01T | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥904.0bn | at 2021-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥212.6bn | at 2022-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥205.3bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥202.9bn | at 2021-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥200.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥60.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥141.5bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥66.7bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥31.6bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥78.5bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥40.5bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥37.9bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥70.9bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥25.1bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥53.37 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥23.75 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥117.45 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥66.11 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥29.22 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥53.35 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥23.74 | 2022-07-01 → 2022-09-30d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥117.38 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥66.07 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥29.2 | 2021-07-01 → 2021-09-30d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 70.6% | at 2022-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 68.7% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 66.0% | at 2021-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2022-09-30 | ¥124m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | ¥275m |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥74.0bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥9.1bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥235.4bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥52.9bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥93.8bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥8.1bn |
| —segment total | revenue external | 2022-04-01 → 2022-09-30 | ¥403.2bn |
| —segment total | segment profit | 2022-04-01 → 2022-09-30 | ¥70.2bn |
| Reconciling Itemsreconciling | revenue external | 2021-04-01 → 2021-09-30 | ¥124m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥1.8bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥58.2bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥11.8bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥194.3bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥50.8bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥92.0bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥13.4bn |
| —segment total | revenue external | 2021-04-01 → 2021-09-30 | ¥344.5bn |
| —segment total | segment profit | 2021-04-01 → 2021-09-30 | ¥76.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 696
| Item | Context | Value | Unit |
|---|---|---|---|
| Cash and cash equivalents IFRS (5-year summary) | Prior1YearInstant | 205251000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 759521040 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 759521040 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 759521040 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 759521040 | |
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 172180000 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.2286 | |
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 81965000 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.1088 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 33615000 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.0446 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 24422000 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0324 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 15736000 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0209 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 14720000 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0195 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 12607000 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0167 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 11224000 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0149 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 10797000 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0143 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 10653000 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0141 | |
| Number of shares held | CurrentQuarterInstant | 387919000 | |
| Shareholding ratio | CurrentQuarterInstant | 0.5151 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 6354100 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 7530197 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 753019700 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 147240 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 759521040 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 7530197 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 6354100 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 6354100 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0084 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 6354100 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 6354100 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.0084 | |
| Cash and cash equivalents IFRS | Prior1YearInstant | 205251000000 | JPY |
| Cash and cash equivalents IFRS | CurrentQuarterInstant | 212550000000 | JPY |
| Trade and other receivables ca IFRS | Prior1YearInstant | 135998000000 | JPY |
| Trade and other receivables ca IFRS | CurrentQuarterInstant | 144515000000 | JPY |
| Other financial assets ca IFRS | Prior1YearInstant | 63000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |